Get the Stockscreener App
48.00
0.48%
-0.23
After Hours:
48.00
Prestige Consumer Healthcare Inc stock is traded at $48.00, with a volume of 947.40K.
It is down -0.48% in the last 24 hours and down -16.10% over the past month.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
See More
Previous Close:
$48.23
Open:
$48.19
24h Volume:
947.40K
Relative Volume:
1.58
Market Cap:
$2.27B
Revenue:
$1.10B
Net Income/Loss:
$186.50M
P/E Ratio:
12.69
EPS:
3.7817
Net Cash Flow:
$267.19M
1W Performance:
+2.67%
1M Performance:
-16.10%
6M Performance:
-19.22%
1Y Performance:
-43.54%
1-Day Range:
$47.18
$48.42
1-Week Range:
$45.57
$48.49
52-Week Range:
$42.62
$87.12
Prestige Consumer Healthcare Inc Stock (PBH) Company Profile
Name
Prestige Consumer Healthcare Inc
Sector
Phone
(914) 524-6800
Address
660 WHITE PLAINS RD., TARRYTOWN, NY
Compare PBH vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBH
Prestige Consumer Healthcare Inc
|
48.00 | 2.28B | 1.10B | 186.50M | 267.19M | 3.7817 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Prestige Consumer Healthcare Inc Stock (PBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Upgrade | Sidoti | Neutral → Buy |
| Dec-09-24 | Downgrade | Sidoti | Buy → Neutral |
| Jun-21-24 | Upgrade | DA Davidson | Neutral → Buy |
| Nov-17-22 | Initiated | Canaccord Genuity | Buy |
| May-10-22 | Upgrade | Jefferies | Hold → Buy |
| May-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-07-20 | Downgrade | DA Davidson | Buy → Neutral |
| Jun-29-20 | Upgrade | Sidoti | Neutral → Buy |
| Apr-14-20 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-20 | Resumed | Sidoti | Neutral |
| Mar-26-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-24-20 | Initiated | Oppenheimer | Perform |
| Mar-19-20 | Upgrade | DA Davidson | Neutral → Buy |
| Jan-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-04-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-02-17 | Upgrade | Jefferies | Underperform → Hold |
| May-22-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-27-16 | Reiterated | B. Riley & Co. | Buy |
| Nov-17-16 | Initiated | Gabelli & Co | Buy |
| Aug-12-16 | Upgrade | Sidoti | Neutral → Buy |
| Mar-08-16 | Initiated | KeyBanc Capital Mkts | Overweight |
| Feb-05-16 | Initiated | Piper Jaffray | Overweight |
| Nov-30-15 | Downgrade | Jefferies | Hold → Underperform |
| Apr-28-14 | Reiterated | B. Riley & Co. | Buy |
| Apr-28-14 | Reiterated | Oppenheimer | Outperform |
| Jul-09-13 | Initiated | B. Riley & Co. | Buy |
View All
Prestige Consumer Healthcare Inc Stock (PBH) Latest News
Why Is Prestige Consumer Healthcare Stock Trending - Kalkine Media
PBH Investors Have Opportunity to Join Prestige Consumer Healthcare Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Prestige Consumer Healthcare Inc. (PBH) Investors to Inquire about Securities Investigation - ACCESS Newswire
Kinetics Spin-Off and Corporate Restructuring Fund's Prestige Consumer Healthcare Inc(PBH) Holding History - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Prestige Consumer H - The National Law Review
Prestige Consumer Healthcare, Inc. (PBH) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc.PBH - PR Newswire
Levi & Korsinsky Announces Investigation of Securities Claims Against Prestige Consumer Healthcare (PBH) - GlobeNewswire
Prestige Consumer Healthcare Inc. (PBH) Q4 2026 Earnings Call Transcript Summary - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Prestige Consumer Healthcare (PBH) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
PBH Investor Alert: Levi & Korsinsky Investigates Prestige Consumer Healthcare (PBH) for Potential Securities Fraud - marketscreener.com
INVESTOR ALERT: Investigation of Prestige Consumer Healthcare Inc. (PBH) announced by Holzer & Holzer, LLC - GlobeNewswire
Prestige Consumer Healthcare (PBH) Valuation After Missed Q4 Targets And Delayed LaCorium Deal Disclosure - Sahm
PBH SHAREHOLDER INVESTIGATION: SueWallSt Investigates Prestige Consumer Healthcare for Possible Securities Law Violations - PR Newswire
Prestige Consumer Healthcare (PBH): Investor Outlook Reveals 48.88% Potential Upside - DirectorsTalk Interviews
Prestige Consumer Healthcare Q4 earnings call highlights - MSN
Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Prestige Consumer Healthcare Inc. Just Missed EPS By 8.9%: Here's What Analysts Think Will Happen Next - 富途牛牛
Prestige Consumer Healthcare: Better Valuation, But Too Much Uncertainty To Buy - Seeking Alpha
Bessemer Group Inc. Acquires 32,331 Shares of Prestige Consumer Healthcare Inc. $PBH - MarketBeat
How InvestingPro’s Fair Value spotted Prestige Healthcare’s 46% drop By Investing.com - Investing.com
Prestige Consumer Healthcare (PBH) Is Down 11.0% After Earnings Miss And Surprise LaCorium Deal DisclosureWhat's Changed - Sahm
PBH Maintains Buy Rating, Price Target Lowered to $72 by Canacco - GuruFocus
Prestige Consumer Healthcare Balances Setbacks With Growth Plan - The Globe and Mail
Securities Fraud Investigation Into Prestige Consumer Healthcare (PBH) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Prestige Consumer Healthcare, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Prestige Consumer Healthcare (PBH) - Morningstar
Investigation launched over Prestige Consumer Healthcare's missed financial targets and undisclosed acquisition. - Pluang
Prestige Consumer Healthcare Inc. Just Missed EarningsBut Analysts Have Updated Their Models - Yahoo Finance
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q4 2026 Earnings Call Transcript - Insider Monkey
Prestige Consumer Healthcare Hits Day Low of $42.66 Amid Price Pressure - Markets Mojo
Prestige Consumer Healthcare Hits New 52-Week Low at $42.66 - Markets Mojo
Prestige Brands stock price target cut to $72 by Canaccord on sales miss - Investing.com Australia
Prestige Consumer Healthcare Inc. $PBH Shares Purchased by Leeward Investments LLC MA - MarketBeat
Oppenheimer downgrades Prestige Consumer Healthcare (PBH) - MSN
Prestige Consumer Healthcare Q4 Earnings Call Highlights - sharewise.com
Prestige Consumer Healthcare Inc. Overview: Major Brands, Competitive Strengths, and Growth Strategy in OTC Health Products - Minichart
PBH News | PRESTIGE CONSUMER HEALTHCARE (NYSE:PBH) - ChartMill
Prestige Consumer Healthcare Inc (PBH) Q4 2026 Earnings Call Hig - GuruFocus
Prestige Consumer Shares Slide on Weak Outlook, 4Q Underperformance - Moomoo
Prestige Consumer (PBH) Experiences Significant Decline - GuruFocus
How Prestige Consumer Healthcare Inc. (PBH) Affects Rotational Strategy Timing - Stock Traders Daily
Prestige Consumer Healthcare Inc (PBH) Shares Fall 11.3% -- What GF Score of 67 Tells Investors - GuruFocus
Prestige Consumer Healthcare forecasts $1.1B-$1.12B fiscal 2027 revenue with Clear Eyes growth weighted to the back half - MSN
Prestige Consumer (PBH) Downgraded by Oppenheimer Following Disa - GuruFocus
Prestige Consumer Hlthcr 4Q EPS $1.13 >PBH - Moomoo
Prestige Consumer Healthcare Inc. FY 2026: Revenue $1.09B, EPS $3.91— 10-K Summary - TradingView
OTC brand leader Prestige Consumer (PBH) outlines growth strategy and risks - Stock Titan
Prestige Consumer (PBH) CFO logs tax-related share withholding adjustment - Stock Titan
Prestige Consumer Healthcare Fiscal Q4 Adjusted Earnings, Revenue Fall; Issues Fiscal 2027 Guidance - Moomoo
Step Back in Clear Eyes Recovery and Macro Challenges Weigh on Prestige in Near Term - Morningstar
Prestige Consumer Healthcare Attributes Soft Results to Low Eye Care Sales, Weak Consumer Backdrop - marketscreener.com
Prestige Consumer Healthcare Inc Stock (PBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):